Journal
JOURNAL OF RHEUMATOLOGY
Volume 45, Issue 8, Pages 1173-1179Publisher
J RHEUMATOL PUBL CO
DOI: 10.3899/jrheum.170326
Keywords
INTERLEUKINS; BIOLOGICAL THERAPY; GROWTH; JUVENILE IDIOPATHIC ARTHRITIS
Categories
Funding
- F. Hoffmann-La Roche Ltd.
- Janssen
- Pfizer
- UCB Biosciences GmbH
- Novartis
- Roche
- Sanofi
Ask authors/readers for more resources
Objective. Evaluate growth in patients with polyarticular-course juvenile idiopathic arthritis (pcJIA) treated with tocilizumab (TCZ) for up to 2 years in a phase III trial. Methods. Patients with pcJIA lasting at least 6 months and inadequate response to methotrexate received open-label TCZ intravenously every 4 weeks (randomly assigned to 8 or 10 mg/kg if they weighed <30 kg; received 8 mg/kg if they weighed >= 30 kg) for 16 weeks. Patients with JIA American College of Rheumatology 30 response at Week 16 were randomly assigned to TCZ or placebo for 24 weeks, with an open-label extension through Week 104. Mean +/- SD height velocity (cm/yr) and World Health Organization (WHO) height SD score (SDS) were measured in patients receiving >= 1 dose of TCZ who did not receive growth hormone and in patients whose baseline Tanner stage was <= 3. Results. The study included 187 of 188 patients (99.5%) with mean WHO height SDS -0.5 +/- 1.2, which was unrelated to age or disease duration (Spearman rank correlations r = 0.08 and r = -0.12, respectively). There were 123 patients at Tanner stage <= 3 at baseline, among whom 103 completed the study with 2 years of height SDS data. Mean height SDS increased from baseline to year 2 (+0.40, p < 0.0001). In 74 of 103 patients (72%), height SDS was greater than at baseline, and mean height velocity was 6.7 +/- 2.0 cm/year. Conclusion. Among patients with pcJIA at Tanner stage <= 3 at baseline, 72% (74/103) had increased height SDS at the end of the study.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available